Evidence map›Paper›PMID 30674394›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2019

[Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases].

Meirong Liu, Fanlu Meng, Qing Ma, Liyan Gu, Diansheng Zhong

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Meirong LiuDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Fanlu MengDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Qing MaDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Liyan GuDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Diansheng ZhongDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Tianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.

Indexed as

Carcinoma, Non-Small-Cell LungDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsFatal OutcomeHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsTreatment OutcomeEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFR-TKILung neoplasmsPrimary resistance

Identifiers

PMID30674394
PMCPMC6348160
OpenAlexW2998515424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.